[go: up one dir, main page]

MA42519A - Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique - Google Patents

Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Info

Publication number
MA42519A
MA42519A MA042519A MA42519A MA42519A MA 42519 A MA42519 A MA 42519A MA 042519 A MA042519 A MA 042519A MA 42519 A MA42519 A MA 42519A MA 42519 A MA42519 A MA 42519A
Authority
MA
Morocco
Prior art keywords
treatment
diabetic nephropathy
pde4 inhibitor
pde4
inhibitor
Prior art date
Application number
MA042519A
Other languages
English (en)
Inventor
Guido Hanauer
Masatoshi Hazama
Takanori Matsuo
Stephanie Vollert
Original Assignee
Takeda Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Gmbh filed Critical Takeda Gmbh
Publication of MA42519A publication Critical patent/MA42519A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA042519A 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique MA42519A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29

Publications (1)

Publication Number Publication Date
MA42519A true MA42519A (fr) 2018-06-06

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042519A MA42519A (fr) 2015-07-29 2016-07-28 Inhibiteur de la pde4 pour le traitement de la néphropathie diabétique

Country Status (9)

Country Link
US (1) US20200179369A1 (fr)
EP (1) EP3328381A1 (fr)
JP (1) JP2018521077A (fr)
CN (1) CN108135886A (fr)
BR (1) BR112018001116A2 (fr)
CA (1) CA2992796A1 (fr)
EA (1) EA201890346A1 (fr)
MA (1) MA42519A (fr)
WO (1) WO2017017165A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3503892A1 (fr) * 2016-08-26 2019-07-03 Takeda GmbH Traitement de la stéatose hépatique non alcoolique
CN107157999A (zh) * 2017-05-27 2017-09-15 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281A (zh) * 2020-08-10 2022-02-18 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2464561A1 (fr) * 2001-10-25 2003-05-01 Depomed, Inc. Traitement utilisant une dose posologique de losartan a retention gastrique
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
PL1723135T3 (pl) * 2004-03-03 2013-11-29 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4

Also Published As

Publication number Publication date
BR112018001116A2 (pt) 2018-09-11
CN108135886A (zh) 2018-06-08
CA2992796A1 (fr) 2017-02-02
US20200179369A1 (en) 2020-06-11
EA201890346A1 (ru) 2018-08-31
EP3328381A1 (fr) 2018-06-06
WO2017017165A1 (fr) 2017-02-02
JP2018521077A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
EP3313325A4 (fr) Échafaudages implantables pour le traitement de la sinusite
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3288592A4 (fr) Utilisation de cannabidiol pour le traitement de spasmes infantiles
EP3388004A4 (fr) Instrument de traitement
MA41449A (fr) Polythérapies pour le traitement de cancers
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
DK3307262T3 (da) Forbindelser til anvendelse ved behandling af neuromuskulære lidelser
ME03474B (fr) Agonistes d'apj 4-hydroxy-3-(hétéroaryl)pyridine-2-one à utiliser dans le traitement de troubles cardio-vasculaires
EP3380062A4 (fr) Compositions pour le traitement des cheveux
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3405188A4 (fr) Traitement pour la modulation du microbiote intestinal
MA42999A (fr) Polythérapie pour le traitement de malignités
EP3328374A4 (fr) Antagonistes de la glutamine pour le traitement de déficits cognitifs
EP3374502A4 (fr) Procédés pour le traitement de dystrophies cornéennes
EP3124129C0 (fr) Appareil à pyrolise pour le traitement de déchets domestiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3375108A4 (fr) Traitement dewlan
EP3349793A4 (fr) Anti-s100a8 pour le traitement de la leucémie
EP3347032A4 (fr) Traitement de l'ascite
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
EP3386593A4 (fr) Composition immunomodulatrice pour le traitement
EP3411073A4 (fr) Combinaisons pour le traitement du cancer